Rhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the Australian Therapeutic Goods Administration (TGA) for approval. The filing is a significant milestone for the Company who are hoping to launch their product to market later this year. Rhythm’s test offers a convenient and non-invasive
Read More
We recently had a one-on-one meeting with Mr. Glenn Gilbert, CEO of Rhythm Biosciences (ASX: RHY). As we do not cover the stock, the main purpose of this call was to get an initial understanding of the Company’s business model as we develop our knowledge on the stock. RHY is a cancer diagnostics technology developer,
Read More
Aussie medtech company Rhythm Biosciences (ASX: RHY) is set to improve the screening process of colorectal cancer with manufacturing of their ColoSTAT testing kit to commence shortly after having appointed Biotem Limited as their new global manufacturer. Colorectal cancer is the third biggest cause for cancer deaths globally where current screening processes tend only to
Read More